Home /
Novartis revives growth despite losing patents on Entresto Novartis returned to growth in the first half of 2026 despite losing patents on its flagship drug Entresto.
Published 7sem · 1 source Notable · updated 1sem
The fact The Swiss pharmaceutical group is betting on new treatments to offset this decline.
Financial markets remain cautious amid sector volatility.
🔗 Click the link to read an article on the topic:
Why it matters La performance de Novartis est un indicateur clé pour le secteur pharmaceutique, marqué par des défis liés à la perte de brevets et à l'innovation, avec des répercussions sur les marchés boursiers.
What if you saw the whole news differently? Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page. → Suisse · © OpenStreetMap, OpenMapTiles, OpenFreeMap World map → Auto-synthesis from 1 media source · identified on July 21, 2026